Publications by authors named "Donald Moore"

Claim this Profile
R
Rilzabrutinib and Bruton tyrosine kinase inhibition for the treatment of persistent or chronic immune thrombocytopenia.
Donald C Moore, P Christopher Parish, Justin R Arnall, Joseph B Elmes

Expert Opin Pharmacother· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the efficacy and safety of initial high-dose romiplostim for primary immune thrombocytopenia in the acute care setting.
Grace Bringhurst, P Christopher Parish, Hang Zeng, Danielle Boselli, Joseph B Elmes, Donald C Moore

Blood Coagul Fibrinolysis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence.
Donald C Moore, Grace Elsey, Jessica McElwee, Shebli Atrash

Expert Opin Biol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ONS/ASCO Guideline on the Management of Antineoplastic Extravasation.
Tanya Thomas, Caroline Clark, Chelsea Backler, Kari Bohlke, Deena Centofanti, Donald C Moore

JCO Oncol Pract· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ONS/ASCO Guideline on the Management of Antineoplastic Extravasation.
Tanya Thomas, Caroline Clark, Chelsea Backler, Kari Bohlke, Deena Centofanti, Donald C Moore

Clin J Oncol Nurs· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncology stewardship practice in the United States: A Hematology/Oncology Pharmacy Association national survey.
Marisela Tan Banez, Sol Atienza, Allison Butts, Megan Derba, Katie Dicke, Donald C Moore

J Oncol Pharm Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporating pharmacoequity in the formulary review and evaluation process: Opportunities for health-system P&T committees to address health disparities and inequities.
Donald C Moore, Angela Colella, Janine S Douglas, Elizabeth A Shlom, Joshua P Vanderloo

Am J Health Syst Pharm· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated, HR-positive, HER2-negative invasive breast cancer: A systematic review.
Chris Larck, Joseph B Elmes, R Wesley Haynes, Donald C Moore

J Oncol Pharm Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice.
Matthew R Peery, Hailey Hill, Amanda Sharps, Aarti Zaver, Donald C Moore

Ann Pharmacother· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma.
James A Davis, Jordan Snyder, Mikhaila Rice, Donald C Moore, Christopher Cahoon

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A second chance for avatrombopag in chemotherapy-induced thrombocytopenia.
Hanny Al-Samkari, Donald C Moore

Br J Haematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proximal complement inhibitors in paroxysmal nocturnal hemoglobinuria: an abundance of options in a rare disease.
Taylor S White, Justin R Arnall, Paul Christopher Parish, Jamie Tolerico, Thuy Tran, Donald C Moore

Expert Rev Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omidubicel for Hematopoietic Cell Transplants: Considerations for Patients and Treatment Outcomes.
Allison L Morse, Hana Kurz, Donald C Moore

Patient Prefer Adherence· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab Infusion-Related Reactions: Multicenter Retrospective Evaluation of Incidence, Severity, and Risk Factors.
Erin Hickey Zacholski, Sarah Rugh, Jenna Marshall, Pramit Nadpara, Donald Moore

J Adv Pract Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis.
Joseph B Elmes, Jessica M Davis, Laura W Musselwhite, Zane Chiad, Donald C Moore

Melanoma Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Investigation of Assessment Scores, Self-Efficacy, and Clinical Practice: Are They Related?
Katie Stringer Lucero, Donald E Moore

J CME· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous Infusion of Turoctocog Alfa in Patients With Mild to Moderate Hemophilia A: A Case Series.
Megan Wayman, Loan Nguyen, Donald C Moore, Mary Ann Knovich, Justin Arnall

Am J Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical outcomes with fostamatinib for the treatment of refractory chronic immune thrombocytopenia: a single-center experience.
Donald C Moore, Joseph B Elmes, Justin R Arnall, Mauricio Pineda-Roman

Blood Coagul Fibrinolysis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.
Caroline Fleck, Allison Karabinos, Allene Cook, Donald C Moore, Ryan Jacobs

Leuk Lymphoma· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacist perspectives on emerging T cell-engaging bispecific therapies in cancer therapeutics.
Donald C Moore, Naomi Digiantonio, Carolyn J Oxencis, Kate D Taucher

Am J Health Syst Pharm· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.
Donald C Moore, Katelynn Granger, Hailey Hill, Allison Karabinos, James A Davis

Expert Rev Hematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase () Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center.
D Grace Nguyen, Sarah A Morris, Alicia Hamilton, Simeon O Kwange, Nury Steuerwald, Donald C Moore

JCO Precis Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series.
D Grace Nguyen, Sarah A Morris, Annabel Chen, Donald C Moore, Sarah L Hanson

J Natl Compr Canc Netw· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib.
Justin Arnall, Lindsey Lyle, Donald C Moore

J Adv Pract Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
Donald C Moore, Joseph B Elmes, Justin R Arnall, Scott A Strassel, Jai N Patel

Int Immunopharmacol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis